Programmed death ligand-1 expression in non-small cell lung cancer in a Western Australian population and correlation with clinicopathologic features
Access Status
Authors
Date
2018Type
Metadata
Show full item recordCitation
Source Title
ISSN
School
Collection
Abstract
© 2018, United States & Canadian Academy of Pathology. Immune checkpoint inhibition is an important therapeutic option in patients with non-small cell lung cancer. Programmed cell death ligand-1 (PD-L1) expression may serve as a predictive marker for anti-PD-1/PD-L1 therapies. The relationship between non-small cell lung cancer PD-L1 expression and clinicopathological characteristics remains unclear and there is no population level Australian data. We report the results of PD-L1 testing in patients with non-small cell lung cancer diagnosed at major Western Australian public hospitals served by a single state Pathology provider. We analyzed PD-L1 expression by immunohistochemistry in 241 non-small cell lung cancer specimens using the 22C3 clone on a Dako autostainer platform. Tumor cell PD-L1 expression was scored as Tumor Proportion Score and categorized using pre-specified subsets of 1%, 1–49% and = 50% for correlation with clinicopathologic features. PD-L1 Tumor Proportion Score was 1% in 65 (27%) cases, 1–49% in 100 (41%) cases and = 50% in 76 (32%) cases. PD-L1-positive rate was 92% in squamous cell carcinomas and 67% in adenocarcinomas. PD-L1 Tumor Proportion Score was higher in squamous cell carcinomas (p = 0.004) and lower in adenocarcinomas (p = 0.003). Of the 196 non-squamous carcinomas, 35% had rat sarcoma viral oncogene homolog (RAS) mutations, 13% had epidermal growth factor receptor (EGFR) mutations, 2% had anaplastic lymphoma kinase (ALK) translocations and 2% had ROS1 translocations. Tumor Proportion Score = 50% was seen in 34% (23/68), 28% (7/25) and 25% (1/4) of RAS, EGFR mutant, and ALK translocated carcinomas, respectively. There was no significant correlation between PD-L1 expression and molecular or genetic abnormalities, or other parameters including age, gender, stage, and smoking status. In our patient cohort, PD-L1 Tumor Proportion Score was significantly higher in squamous cell carcinomas and lower in adenocarcinomas. The overall prevalence of Tumor Proportion Score = 50% is consistent with that reported in clinical trials.
Related items
Showing items related by title, author, creator and subject.
-
Kannaiyan, R.; Manu, K.; Chen, L.; Li, F.; Rajendran, P.; Subramaniam, A.; Lam, P.; Kumar, Alan Prem; Sethi, G. (2011)Celastrol, a plant triterpene has attracted great interest recently, especially for its potential anti-inflammatory and anti-cancer activities. In the present report, we investigated the effect of celastrol on proliferation ...
-
Hammerman, P.; Voet, D.; Lawrence, M.; Voet, D.; Jing, R.; Cibulskis, K.; Sivachenko, A.; Stojanov, P.; McKenna, A.; Lander, E.; Gabriel, S.; Getz, G.; Imielinski, M.; Helman, E.; Hernandez, B.; Pho, N.; Meyerson, M.; Chu, A.; Hye-Chun, J.; Mungall, A.; Pleasance, E.; Robertson, A.; Sipahimalani, P.; Stoll, D.; Balasundaram, M.; Birol, I.; Butterfield, Y.; Chuah, E.; Coope, R.; Corbett, R.; Dhalla, N.; Guin, R.; He, A.; Hirst, C.; Hirst, M.; Holt, R.; Lee, D.; Li, H.; Mayo, M.; Moore, R.; Mungall, K.; Nip, K.; Olshen, A.; Schein, J.; Slobodan, J.; Tam, A.; Thiessen, N.; Varhol, Richard; Zeng, T.; Zhao, Y.; Jones, S.; Marra, M.; Saksena, G.; Cherniack, A.; Schumacher, S.; Tabak, B.; Carter, S.; Nguyen, H.; Onofrio, R.; Crenshaw, A.; Ardlie, K.; Beroukhim, R.; Winckler, W.; Protopopov, A.; Zhang, J.; Hadjipanayis, A.; Lee, S.; Xi, R.; Yang, L.; Ren, X.; Zhang, H.; Shukla, S.; Chen, P.; Haseley, P.; Lee, E.; Chin, L. (2012)Lung squamous cell carcinoma is a common type of lung cancer, causing approximately 400,000 deaths per year worldwide. Genomic alterations in squamous cell lung cancers have not been comprehensively characterized, and no ...
-
Lattanzio, R.; Marchisio, M.; La Sorda, R.; Tinari, N.; Falasca, Marco; Alberti, S.; Miscia, S.; Ercolani, C.; Di Benedetto, A.; Perracchio, L.; Melucci, E.; Iacobelli, S.; Mottolese, M.; Natali, P.; Piantelli, M. (2013)Phospholipase Cγ1 (PLCγ1) is highly expressed in several tumors. We have previously reported that both stable and inducible PLCγ1 down-regulation resulted in an almost complete inhibition of breast cancer-derived experimental ...